Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Colorcon
Boehringer Ingelheim
Dow
Johnson and Johnson
AstraZeneca
Mallinckrodt

Last Updated: October 19, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR TIAGABINE HYDROCHLORIDE

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Tiagabine Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00015132 Tiagabine, Sertraline, or Donepezil for the Treatment of Cocaine Dependence - 9 Completed National Institute on Drug Abuse (NIDA) Phase 2 1999-03-01 The purpose of this CREST (Clinical Rapid Evaluation Screening Trial) study is the use of tiagabine, sertraline, or donepezil for the treatment of cocaine dependence using a modified placebo-controlled experimental design.
NCT00015769 Pilot Study of Levetiracetam (Keppra® (Registered Trademark)) for Bipolar Illness Completed National Institute of Mental Health (NIMH) Phase 2 2001-04-01 This study will explore the possible effectiveness of levetiracetam in patients with bipolar illness who have not responded adequately to standard treatments. Levetiracetam was recently approved to treat seizures. Other drugs in the same class as levetiracetam, including carbamazepine and valproate, are widely recognized as substitute medications for lithium or are used as an adjunct to it, and other anticonvulsants have also shown promise in improving bipolar symptoms. Patients with bipolar illness whose manic, depressed or unstable moods are not adequately controlled by their current treatment and who have not responded previously to two standard treatments (i.e., lithium, valproate, carbamazepine or neuroleptics) may be eligible for this study. Participants will take levetiracetam starting at 500 mg daily. If this dose is well tolerated, it will be increased to 500 mg twice a day. Every 3 days, doses may be increased until the target dose of 3000 mg/day is reached. Higher doses, not to exceed 4000 mg/day, may be tried in patients who do not respond fully to the lower doses. Patients and observers will use standard ratings to evaluate the patients' response to therapy during the 8-week study. If, after 8 weeks, the results appear promising, patients may continue treatment for an additional 6 months to evaluate longer-term effects.
NCT00068770 Celecoxib in Patients With Newly Diagnosed GBM Who Are Receiving Anticonvulsant Drugs and Undergoing RT Terminated National Cancer Institute (NCI) Phase 2 2003-10-01 RATIONALE: Celecoxib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. It is not yet known whether the effectiveness of celecoxib in treating glioblastoma multiforme is decreased in patients who are receiving anticonvulsant drugs and undergoing radiation therapy. PURPOSE: Phase II trial to study the effectiveness of celecoxib in treating patients who are receiving anticonvulsant drugs and undergoing radiation therapy for newly diagnosed glioblastoma multiforme.
NCT00068770 Celecoxib in Patients With Newly Diagnosed GBM Who Are Receiving Anticonvulsant Drugs and Undergoing RT Terminated Sidney Kimmel Comprehensive Cancer Center Phase 2 2003-10-01 RATIONALE: Celecoxib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. It is not yet known whether the effectiveness of celecoxib in treating glioblastoma multiforme is decreased in patients who are receiving anticonvulsant drugs and undergoing radiation therapy. PURPOSE: Phase II trial to study the effectiveness of celecoxib in treating patients who are receiving anticonvulsant drugs and undergoing radiation therapy for newly diagnosed glioblastoma multiforme.
NCT00086255 Tiagabine for the Treatment of Cocaine Dependence - 1 Completed University of Cincinnati Phase 2 2002-10-01 The purpose of this study is to assess tiagabine for the treatment of cocaine dependence.
NCT00086255 Tiagabine for the Treatment of Cocaine Dependence - 1 Completed National Institute on Drug Abuse (NIDA) Phase 2 2002-10-01 The purpose of this study is to assess tiagabine for the treatment of cocaine dependence.
NCT00129298 Effectiveness of Tiagabine for Cocaine Dependence in Methadone-Maintained Individuals - 1 Completed National Institute on Drug Abuse (NIDA) Phase 2 2004-12-01 Many opioid-dependent individuals are also dependent on cocaine. Methadone is a widely used and effective method for treating opioid dependence. However, it is not effective in treating other drugs of abuse. The purpose of this study is to determine the effectiveness of another drug, tiagabine, for treating cocaine dependence in opioid-dependent individuals already receiving methadone treatment.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Tiagabine Hydrochloride

Condition Name

Condition Name for Tiagabine Hydrochloride
Intervention Trials
Cocaine-Related Disorders 5
Epilepsy 2
Alcoholism 2
Chronic Idiopathic Axonal Polyneuropathy 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Tiagabine Hydrochloride
Intervention Trials
Cocaine-Related Disorders 5
Anxiety Disorders 3
Epilepsy 3
Epilepsies, Partial 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Tiagabine Hydrochloride

Trials by Country

Trials by Country for Tiagabine Hydrochloride
Location Trials
United States 43
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Tiagabine Hydrochloride
Location Trials
Massachusetts 6
Pennsylvania 3
Georgia 3
Maryland 3
Ohio 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Tiagabine Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Tiagabine Hydrochloride
Clinical Trial Phase Trials
Phase 4 5
Phase 3 2
Phase 2 8
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Tiagabine Hydrochloride
Clinical Trial Phase Trials
Completed 14
Terminated 3
Unknown status 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Tiagabine Hydrochloride

Sponsor Name

Sponsor Name for Tiagabine Hydrochloride
Sponsor Trials
National Institute on Drug Abuse (NIDA) 5
Cephalon 2
GlaxoSmithKline 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Tiagabine Hydrochloride
Sponsor Trials
Other 13
Industry 7
NIH 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Medtronic
Boehringer Ingelheim
AstraZeneca
Baxter
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.